Fertility concerns influence treatment decisions in younger patients with breast cancer
the ONA take:
Previous studies have shown that following a 5-year course of tamoxifen after breast cancer treatment can reduce recurrence by 47% and mortality by 26%.
In addition, more recent data suggests taking tamoxifen for 10 years may be even more beneficial. However, many patients with breast cancer, especially premenopausal women, decline the therapy or discontinue it in less than 5 years.
This study found that 13% of patients declined tamoxifen therapy and 16% stopped before the recommended 5 years of treatment were up.
Phone interviews conducted with 88 patients who did not initiate or discontinued tamoxifen revealed concerns about fertility and side effects were primary factors for these patients’ decision.
The researchers conclude these findings demonstrate a need to include appropriate counseling for patients who express concerns about future fertility at the outset as part of a multidisciplinary treatment plan.
They suggested that a dialog about fertility could identify more patients willing to complete the recommended course if they could delay or take a break from the therapy to allow for pregnancy.
A new international trial, called POSITIVE, being conducted by the International Breast Cancer Study Group, is looking at whether premenopausal women who take a hiatus to become pregnant then resume the therapy would have similar benefit as those who taken tamoxifen continuously for 5 years.
Previous studies have shown that following a 5-year course of tamoxifen after breast cancer treatment can reduce recurrence.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|